Syngene International a research company has entered into a non-exclusive partnering agreement with Zumutor Biologics an emerging immuno-oncology company to access Zumutor's proprietary na ve human phage/yeast display library. This collaboration further enhances Syngene's market-leading capabilities in discovery biology providing its scientists with additional tools to help solve complex biology problems in biotherapeutic drug discovery. Read: Union Budget 2018: What experts have to say about healthcare in India? Under the terms of the agreement Syngene will screen target antigens against Zumutor's proprietary human antibody libraries to identify and characterize novel antibody clones which will be further developed by Syngene towards
